NORTH WALES, Pa. — Teva Pharmaceuticals announced the availability of its Levoleucovorin (Fusilev) generic for injection, used to treat toxic effects of methotrexate in people who have received methotrexate to treat bone cancer.
Levoleucovorin is also used to treat or prevent toxic effects of methotextrate in people whose bodies do not eliminate methotextrate properly after the drug is metabolized. It can also be used to treat toxic effects of an accidental methotextrate overdose.
Teva is a division if Teva Pharmaceuticals USA, a wholly owned subsidiary of Israeli-based Teva Pharmaceutical Industries.
Fusilev is manufactured by Spectrum Pharmaceuticals.